Published 6 issues per year
ISSN Print: 1040-8401
ISSN Online: 2162-6472
Indexed in
Effect of Lymphodepletion on Donor T Cells and the Role of Recipient Cells Persisting after Cytotoxic Treatments in Cancer Immunotherapies
ABSTRACT
The effectiveness of lymphodepletion in antitumor immunity has been well established. Although recent studies have elucidated some of the broad mechanisms underlying the augmentation of antitumor immunity by lymphodepletion, such as increased availability of cytokines due to the elimination of cellular elements and improvement in tumor antigen presentation, the precise mechanisms remain unclear. Previous studies have focused on the enhancement of the functions of transferred antitumor CD8+ T cells after lymphodepletion. In this review, we discuss the important role of other immune cells in the effectiveness of lymphodepletion. Recent studies have demonstrated that lymphodepletion enhances not only transferred tumor-specific CD8+ T cells but also tumor-specific CD4+ T cells and polyclonal naïve T cells. Moreover, recipient immune cells, including CD8+ T cells, regulatory T cells, dendritic cells, and macrophages, are involved in the augmentation of antitumor effects by lymphodepletion. These host cells can survive lymphodepletive therapies and play a role in the development of antitumor immunity after lymphodepletion. Improvements in the understanding of lymphodepletion allow us to design effective cancer immunotherapy.
-
Jazaeri Amir, Coleman Robert L., Sood Anil K., Frumovitz Michael M., Soliman Pamela T., Shafer Aaron, Cutrera Jeffry J., Klinger Marlana, Sharafi Sara E., Johnson Cynae A.L., Villanueva Valerie F., Hinchcliff Emily M., Dickens Andrea, Cain Katherine E., Anderson Jaime E., Lu Karen H., Westin Shannon N., A practical guide for the safe implementation of early phase drug development and immunotherapy program in gynecologic oncology practice, Gynecologic Oncology, 151, 2, 2018. Crossref
-
Castelletti Laura, Yeo Dannel, van Zandwijk Nico, Rasko John E. J., Anti-Mesothelin CAR T cell therapy for malignant mesothelioma, Biomarker Research, 9, 1, 2021. Crossref
-
Takahashi Miho, Watanabe Satoshi, Suzuki Ryo, Arita Masashi, Sato Ko, Sato Miyuki, Sekiya Yuki, Abe Yuko, Fujisaki Toshiya, Ohtsubo Aya, Shoji Satoshi, Nozaki Koichiro, Ichikawa Kosuke, Kondo Rie, Saida Yu, Hokari Satoshi, Aoki Nobumasa, Hayashi Masachika, Ohshima Yasuyoshi, Koya Toshiyuki, Kikuchi Toshiaki, PD-1 blockade therapy augments the antitumor effects of lymphodepletion and adoptive T cell transfer, Cancer Immunology, Immunotherapy, 71, 6, 2022. Crossref
-
Tsao Anne S., Pass Harvey I., Rimner Andreas, Mansfield Aaron S., New Era for Malignant Pleural Mesothelioma: Updates on Therapeutic Options, Journal of Clinical Oncology, 40, 6, 2022. Crossref
-
Marhelava Katsiaryna, Krawczyk Marta, Firczuk Malgorzata, Fidyt Klaudyna, CAR-T Cells Shoot for New Targets: Novel Approaches to Boost Adoptive Cell Therapy for B Cell-Derived Malignancies, Cells, 11, 11, 2022. Crossref
-
Hont Amy B., Powell Allison B., Sohai Danielle K., Valdez Izabella K., Stanojevic Maja, Geiger Ashley E., Chaudhary Kajal, Dowlati Ehsan, Bollard Catherine M., Cruz Conrad Russell Y., The generation and application of antigen-specific T cell therapies for cancer and viral-associated disease, Molecular Therapy, 30, 6, 2022. Crossref